Abstract
Most gene mutations associated with Alzheimers disease point to the metabolism of amyloid precursor protein as potential cause. The β- and γ-secretases are two executioners of amyloid precursor protein processing resulting in amyloid β. Significant progress has been made in the selective inhibition of both proteases, regardless of structural information for γ-secretase. Several peptidic and non-peptidic leads were identified and first drug candidates are in clinical trials. This review focuses on the developments since 2003.
Keywords: Alzheimer's disease, secretase, aspartic protease, inhibitor, presenilin
Current Topics in Medicinal Chemistry
Title: Inhibitors and Modulators of β- and γ-Secretase
Volume: 6 Issue: 4
Author(s): Boris Schmidt, Stefanie Baumann, Hannes A. Braun and Gregor Larbig
Affiliation:
Keywords: Alzheimer's disease, secretase, aspartic protease, inhibitor, presenilin
Abstract: Most gene mutations associated with Alzheimers disease point to the metabolism of amyloid precursor protein as potential cause. The β- and γ-secretases are two executioners of amyloid precursor protein processing resulting in amyloid β. Significant progress has been made in the selective inhibition of both proteases, regardless of structural information for γ-secretase. Several peptidic and non-peptidic leads were identified and first drug candidates are in clinical trials. This review focuses on the developments since 2003.
Export Options
About this article
Cite this article as:
Schmidt Boris, Baumann Stefanie, Braun A. Hannes and Larbig Gregor, Inhibitors and Modulators of β- and γ-Secretase, Current Topics in Medicinal Chemistry 2006; 6 (4) . https://dx.doi.org/10.2174/156802606776287027
DOI https://dx.doi.org/10.2174/156802606776287027 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Tumor Dormancy and the Angiogenic Switch: Possible Implications of Bone Marrow- Derived Cells
Current Pharmaceutical Design Structural Analysis of Relevant Drug Targets for Alzheimer's Disease: Novel Approaches to Drug Development
Current Bioactive Compounds Resveratrol: New Avenues for a Natural Compound in Neuroprotection
Current Pharmaceutical Design Renal Complications of Fabry Disease
Current Pharmaceutical Design Cell Culture Models of Oxidative Stress and Injury in the Central Nervous System
Current Neurovascular Research Cognitive Impairment in the Septic Brain
Current Neurovascular Research Aminotransferase Serum Levels Decrease after Initiating Antiretroviral Treatment in HIV Infected Patients
Current HIV Research Interactions Between Plasma Proteins and Naturally Occurring Polyphenols
Current Drug Metabolism Renin-angiotensin System Blockers and Modulation of Radiation-Induced Brain Injury
Current Drug Targets Neurological Disorders in Medical Use of <i>Cannabis</i>: An Update
CNS & Neurological Disorders - Drug Targets Insights into Aβ Aggregation: A Molecular Dynamics Perspective
Current Topics in Medicinal Chemistry Alzheimer’s Disease And Type 2 Diabetes: Exploring The Association To Obesity And Tyrosine Hydroxylase
CNS & Neurological Disorders - Drug Targets The Effects of Combined Omega-3 Fatty Acids and Valproic Acid Supplementation on Symptoms of Borderline Personality Disorder: A Pilot Study
Current Psychopharmacology Arterial Stiffness, Cognitive Dysfunction and Adherence to Antihypertensive Agents. Is there a Link to Hypertensive Patients?
Current Vascular Pharmacology On the Psychotropic Effects of Carbon Dioxide
Current Pharmaceutical Design Complications Associated with Recombinant Tissue Plasminogen Activator Therapy for Acute Ischaemic Stroke
CNS & Neurological Disorders - Drug Targets Molecular Docking Study of a Series of Substituted Xanthone Derivatives as Novel COX-2 Inhibitors Targeting Prostaglandin Endoperoxide Synthase -2
Current Enzyme Inhibition Insulin Resistance as Common Molecular Denominator Linking Obesity to Alzheimer’s Disease
Current Alzheimer Research Ladostigil: A Novel Multimodal Neuroprotective Drug with Cholinesterase and Brain-Selective Monoamine Oxidase Inhibitory Activities for Alzheimers Disease Treatment
Current Drug Targets The Emerging Role of MicroRNA in Schizophrenia
CNS & Neurological Disorders - Drug Targets